COPD Foundation Selected as Finalist for CARE Award
WASHINGTON, D.C. - April 22, 2016 -The COPD Foundation is pleased to announce that it has been selected as a finalist for the Clinical & Research Excellence (CARE) awards in the Best Personalized Medicine Advance or Application category for its work on plasma fibrinogen.
The Chronic Obstructive Pulmonary Disease (COPD) Biomarker Qualification Consortium (CBQC) is a unique public-private partnership among the COPD Foundation, the pharmaceutical industry, academic experts, and the Food and Drug Administration. The intent of the CBQC is to facilitate the qualification of biomarkers that can be used for enrichment of clinical trial populations and/or as outcome assessments. Recently, the FDA approved the qualification of plasma fibrinogen as a prognostic or enrichment biomarker for all-cause mortality and COPD exacerbations. Plasma fibrinogen is the first biomarker drug development tool qualified for use in COPD under the FDA’s Drug Development Tool (DDT) qualification program.
The award recognizes the efforts of an individual, team or company working in the expanding and promising field of personalized medicine. The judges look to recognize one or more of the following achievements: identification or validation of a new biomarker/companion diagnostic, new or innovative use of a new biomarker/companion diagnostic, potential to impact future treatment paradigms, potential to improve either the commercial or clinical outcomes of the therapy.
Winners will be announced at an awards reception in Boston on April 27, 2016.